Adagrasib,Cetuximab,Afatinib,Pembrolizumab
Mirati,Eli Lilly,Boehringer Ingelheim,Merck
['agent']
 2nd line treatments greater in mono vs doublet therapy arm (66% with 43% with follow up for single agent. more data to follow. #esmo22 
Co-Director/Co-Leader GI Oncology Research; Director, Young Adult Cancers Program; Co-Chair, NCI GI Steering Committee; and Director for Strategic Relations